Intech Investment Management LLC Invests $650,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Intech Investment Management LLC acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 13,727 shares of the company's stock, valued at approximately $650,000.

A number of other hedge funds also recently made changes to their positions in the business. Jennison Associates LLC lifted its holdings in Kymera Therapeutics by 85.8% during the 3rd quarter. Jennison Associates LLC now owns 797,681 shares of the company's stock valued at $37,754,000 after purchasing an additional 368,394 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Kymera Therapeutics by 2.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 405,870 shares of the company's stock worth $12,115,000 after buying an additional 10,731 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Kymera Therapeutics by 15.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 402,385 shares of the company's stock worth $12,012,000 after buying an additional 53,176 shares during the period. Driehaus Capital Management LLC acquired a new position in Kymera Therapeutics in the 2nd quarter valued at about $6,669,000. Finally, Bank of New York Mellon Corp raised its holdings in Kymera Therapeutics by 19.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 156,211 shares of the company's stock valued at $4,663,000 after acquiring an additional 25,317 shares during the period.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 15.82% of the stock is owned by company insiders.

Kymera Therapeutics Stock Down 0.0 %

Shares of NASDAQ:KYMR traded down $0.01 during trading on Friday, hitting $46.85. 184,881 shares of the company were exchanged, compared to its average volume of 443,344. Kymera Therapeutics, Inc. has a 1-year low of $19.73 and a 1-year high of $53.27. The company has a market capitalization of $3.03 billion, a P/E ratio of -20.02 and a beta of 2.21. The business's 50 day moving average is $46.82 and its 200-day moving average is $42.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $3.74 million during the quarter, compared to analysts' expectations of $10.34 million. During the same quarter in the prior year, the firm earned ($0.90) EPS. The business's revenue for the quarter was down 20.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

KYMR has been the subject of several research reports. Oppenheimer lifted their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an "outperform" rating in a report on Friday, September 27th. Wolfe Research raised shares of Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 price objective for the company in a report on Monday, August 26th. Morgan Stanley increased their target price on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the stock an "equal weight" rating in a research report on Wednesday, November 6th. Wells Fargo & Company lifted their price target on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an "equal weight" rating in a research report on Monday, August 12th. Finally, Leerink Partnrs raised Kymera Therapeutics to a "strong-buy" rating in a research report on Monday, September 9th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $52.13.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.